Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc. > Summary
Court Case Number IPR2022-00257
Filing Date Dec 9, 2021
Institution Decision Date Feb 9, 2022
Decision Date Nov 9, 2022
Court Patent Trial and Appeal Board
Status Final Written Decision
Appeal2023-1395
Administrative JudgesJohn G. New, Erica A. Franklin, Susan L. C. Mitchell
Judge Writing the Final DecisionJohn G. New
Claims Challenged in the Petition: 1, 8, 9, 10, 11, 12
Claims Instituted: 1, 8, 9, 10, 11, 12
Petitioner
Patent Owner
Petitioner Attorneys
10Celltrion
Attorney Name: Lora M. Green
Wilson Sonsini Goodrich & Rosati
Celltrion
Attorney Name: Yahn Lin Chu
Wilson Sonsini Goodrich & Rosati
Celltrion
Attorney Name: Teresa Stanek Rea
Celltrion
Attorney Name: Paul John Molino
Celltrion
Attorney Name: Shannon M. Lentz
Celltrion
Attorney Name: Deborah H. Yellin
Celltrion
Attorney Name: William A. Rakoczy
Attorney Name: Aviv Zalcenstein
Gemini Law LLP
Attorney Name: Robert Vaughan Cerwinski
Gemini Law LLP
Attorney Name: Brigid M. Morris
Gemini Law LLP
Patent Owner Attorneys
7Regeneron Pharmaceuticals
Attorney Name: Deborah E. Fishman
Arnold & Porter Kaye Scholer
Regeneron Pharmaceuticals
Attorney Name: Alice Ho
Arnold & Porter Kaye Scholer
Regeneron Pharmaceuticals
Attorney Name: Matthew Wilk
Arnold & Porter Kaye Scholer
Regeneron Pharmaceuticals
Attorney Name: Victoria Reines
Arnold & Porter Kaye Scholer
Regeneron Pharmaceuticals
Attorney Name: Jeremy D. Cobb
Arnold & Porter Kaye Scholer
Regeneron Pharmaceuticals
Attorney Name: Daniel L. Reisner
Arnold & Porter Kaye Scholer
Related Patents
Doc No | Title | Issue date |
---|---|---|
09669069 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jun 6, 2017 |